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Introduction: Sporadic inclusion body myositis is the most common adult myopathy in persons aged 50 years and
older. The clinical presentation includes a chronic, slowly progressive course with a predilection for weakness of the
forearm flexors and quadriceps muscles. Its indolent course makes it a disease frequently missed or misdiagnosed
as other neuromuscular conditions by health care professionals. The degenerative processes with amyloid
accumulation distinguish sporadic inclusion body myositis from other inflammatory myopathies. Currently, no
effective therapy exists. This clinical report highlights the difficulties in diagnosing the disease, examples of
misdiagnosis, and inappropriate therapies that can result from misdiagnosis.
Case presentation: We present our clinical experience with 20 patients over a 10-year period and describe in
depth two cases, both men, one of Indian ethnicity and the other of Hispanic ethnicity, who were referred to our
neuromuscular division for second opinions and diagnosed with sporadic inclusion body myositis years after
symptom onset.
Conclusions: Although sporadic inclusion body myositis is rare and without effective therapy, accurate diagnosis is
crucial to providing adequate counseling and information about the prognosis and disease course, and to avoiding
inappropriate therapy.
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Sporadic inclusion body myositis (s-IBM) is one of sev-
eral chronic adult inflammatory myopathies. Its preva-
lence varies, but it may be as high as 35 per 1 million
adults over age 50 years, with a slight male predomin-
ance [1]. The clinical presentation involves chronic,
slowly progressive, distal asymmetric weakness affecting
the finger flexors and proximal lower extremity weak-
ness affecting the quadriceps, which later progresses to
other proximal and distal muscles. The indolent disease
course sometimes lasts many years until patients notice
significant deterioration leading to medical care [2–4].
Additional complaints include dysphagia caused by
cricothyroid muscle weakness and decreased pharyngeal
propulsion [5]. The pathogenesis of s-IBM is not fully
understood, and currently there is no known treatment* Correspondence: rison@usc.edu
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(http://creativecommons.org/publicdomain/ze[3, 6]. We present two exemplary cases followed by a
summary table that highlights the presentation of 20 pa-
tients seen in our clinic over a 10-year period.Case presentations
The local institutional review board approved this study.
The case presentation portions of this report were pre-
pared according to recent standardized guidelines [7–9].Patient 1
A 58-year-old man of Indian ethnicity with type 2 dia-
betes mellitus was referred to our hospital for a second-
opinion neuromuscular evaluation. Four years prior, he
had noted leg weakness, particularly in his thighs. After
initial evaluation and diagnostic studies, his neurologist
had diagnosed him with deconditioning and prescribed
vitamin B12 injections. A subsequent electrodiagnostic
study revealed denervation changes in his upper extrem-
ity muscles and thoracic paraspinal muscles, leading to a
diagnosis of amyotrophic lateral sclerosis (ALS), whichrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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riluzole and advised to plan for end of life.
When referred to our institution, the patient described
weakness while climbing and descending stairs without
upper extremity complaints. During his physical examin-
ation, he was noted to have atrophy in the quadriceps
muscles with moderate weakness. Electromyography
(EMG) showed increased membrane instability and early
recruitment with fractionation of the motor unit poten-
tials, showing a brief, small, abundant, polyphasic motor
unit potential pattern. His creatine kinase (CK) level was
elevated at 647IU/L. A muscle biopsy showed myopathic
features with rimmed vacuoles characteristic of s-IBM.
The patient was informed of his correct diagnosis and
counseled on his prognosis. Patient 1 is represented as
patient 8 in Table 1.
Patient 2
A 54-year-old Hispanic man developed weakness in his
grip, followed 1 year later by lower extremity weakness.
His CK level was 2400IU/L, and a muscle biopsy indi-
cated polymyositis (PM). His initial therapy included
prednisone followed by other immunosuppressive medica-
tions, including azathioprine, methotrexate, and mycophe-
nolate mofetil. Although the patient’s CK level decreased
to 450IU/L, his condition continued to progress. Nine
years later, he was evaluated at our neuromuscular clinic.
At that time, he was unable to get up from a seated
position, locked his knees while ambulating to avoid
falls, and had severe weakness in his left hand and
moderate weakness in his right hand. During his physical
examination, he was noted to have asymmetric atrophy in
the forearm flexor and the quadriceps muscles, with severe
asymmetric weakness of knee extension and slight
weakness in ankle dorsiflexion and plantarflexion. EMG
showed active denervation with significant brief, small,
abundant, polyphasic motor unit potentials. A repeat
muscle biopsy showed variation in muscle fiber size,
endomysial fibrosis, chronic inflammatory cells with
macrophages, and rimmed vacuoles with basophilic
stippling, all characteristic of s-IBM. The patient was coun-
seled on his correct s-IBM diagnosis, and immunosuppres-
sive therapy was discontinued. Patient 2 is represented as
patient 9 in Table 1.
Retrospective chart review
Table 1 shows 20 patients (16 men, 4 women) seen at
our neuromuscular division between 2004 and 2014 (in-
cluding patients 1 and 2 in the present report listed as
patients 8 and 9, respectively). The patients’ average age
at initial evaluation at our clinic was 67.8 years (standard
deviation, 11.5; range, 43–85). The average number of
months from symptom onset to diagnosis was 70.0
(standard deviation, 54.8; range, 6–240). One patient didnot follow up to confirm the diagnosis but was clinically
diagnosed with s-IBM. Our clinic population had char-
acteristics of s-IBM similar to those described in previ-
ous reports. The topography was proximal leg weakness
presenting as difficulty with ambulation and rising from
chairs, in addition to finger flexor weakness presenting
as difficulty handling objects and opening jars and bot-
tles. Four patients had dysphagia.
Several patients were misdiagnosed before evaluation
at our institute: two patients (patients 9 and 17) diag-
nosed with PM who were given immunosuppressive
medications; three (patients 8, 18, and 19) who were di-
agnosed with ALS; one (patient 5) diagnosed with en-
trapment neuropathy who underwent cubital tunnel
release with no improvement; one (patient 14) who was
diagnosed with extrapyramidal symptoms of Parkinson’s
disease versus radiculopathy; and one (patient 16) who
was diagnosed with s-IBM and given etanercept. The
remaining 12 patients were referred without diagnosis or
for second opinions for myopathy.
(Please note the standard deviations given above for
time until the final correct diagnosis, and see below for
discussion of trends and how our findings coincide with
the existing published literature.)
Discussion
s-IBM is both a myodegenerative and neurodegenerative
disease with β-amyloid-related deposits and an inflam-
matory disease with endomysial lymphocytic infiltration.
Accumulation of misfolded proteins and inadequate
intracellular repair mechanisms characterize the disease
[10]. There is also expression of major histocompatibility
complex (MHC) class I molecules [3]. A 43 kDa muscle
protein, recently identified as cytosolic 5′-nucleotidase
1A, was discovered in 2013 as an autoantigen for s-IBM
autoantibodies [11–13]. This finding indicates the poten-
tial role of humoral immunity in the pathogenesis of the
disease in addition to a cytotoxic T-cell-mediated com-
ponent. Furthermore, identification of this target of s-
IBM autoantibodies could lead to the development of a
diagnostic blood test, potentially eliminating the need
for invasive testing such as muscle biopsy.
Although muscle biopsy can confirm the diagnosis of
s-IBM, the results may be negative owing to sampling
error or to end-stage muscle wasting. Endomysial inflam-
mation and degeneration with misfolded protein aggre-
gates and/or inclusions [10] and atrophic fibers [14] are
often present. Congo red staining or immunofluorescence
shows amyloid β-pleated sheets in and around vacuoles
[3]. There are rimmed vacuoles within the myofibril.
In cases where the inclusion bodies are not found, the
presence of inflammation alone can lead to an erroneous
diagnosis of PM [4, 15]. If there is no definite diagnosis,
then biopsy should be repeated.












1 56 24 M Gait difficulty, then
grip weakness
WE 4− (L), FF 2, HF
5− (L), KE 3, DF 2
Myopathic End-stage muscle wasting Possible
myopathy
2 70 60 M Asymmetric leg
weakness, recurrent
falls
HF 4− (L), HE 4−;
HF 3 (R), KE 4−, KF
5−, DF 4,
Myopathic s-IBM strongly confirmed by p62-
positive fibers
Unknown




SA 5−, EF 4−, EE 4
−, FE 4; digits 4




End-stage muscle wasting, no




4 81 48 M Leg weakness, falls,
difficulty getting up
from chair
Mild digit 5 flexion
weakness, HF 4
Myopathic Fibers with adjacent lymphocytes,
inclusions in fibers, interstitial
fibrosis, COX-negative fibers
Comorbid RA
5 85 72 M Difficulty climbing
stairs, then asymmetric
grip weakness






Atrophy with scattered morula,
with mild chronic inflammation
Peripheral
neuropathy
6 67 60 M Grip weakness, then
difficulty getting up
from chair
FF 3, HF 3, KE 2, PF
4
NA Intramyofiber inclusions Unknown




SA 2, EF 2, EE 4, FF
2, FE 4+, HE 4, HA
4, KE 2, KF 4−, DF 4
−, PF 4−
Myopathic NA Unknown




FF 4, HF 5−, HE 5−,
KF 4−, KE 4
Myopathic Chronic and active vacuolar
myopathy, severe IBM
ALS
9 54 145 M Grip weakness, then
leg weakness, getting
up from chair and
ambulation difficulty
FF 3 (R); 4 (L), KE 3
(L), KE 4− (R)
Myopathic 2003: polymyositis Polymyositis
2013: chronic and active vacuolar
myopathy




EF 5−, EE 4+, FF 3
(R) 2 (L), KE 4− (R);
2 (L), HF 4+
Myopathic Intramyofiber inclusions with
fibrosis, absent oxidative positivity
Neuropathy vs.
myopathy





Digits 4 and 5 FF 2
(R); digits 2–5 FF 2
(L), KE 4−, DF 4+
(R); 4− (L), PF 4+
Myopathic Prominent lymphocytic infiltration Unknown
12 73 120 M Proximal leg weakness HE 4, KE 3 Chronic
denervation in
the L4 muscles
Biceps with minimal denervation




13 43 60 M Finger flexor and
proximal leg weakness
HE 4−, KE 3+ (R); 4
− (L)
NA Lymphocytes, myopathy Inflammatory
myopathy vs.
IBM
14 67 24 M Proximal leg weakness,
then finger flexors
HF R 4, KE R 4 (R);









15 75 6 M L leg weakness, L
hand weakness, b/l
arm weakness
SA 4, FF 4−, HF 3,
HA 4, KF 4+, DF 4
+, KE 4−




16 71 120 F Leg weakness, then
hand weakness, then
difficulty swallowing
B 4+ (R); 4 (L); WE
4 (R), FE 3, FF 3, KE
4−
Myopathic Intramyofiber inclusions IBM
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Table 1 Retrospective chart review (Continued)




SA 3 (R); 4− (L), FE
4−, WE 4−, WF 4−,
FF 4−, HF 2, HE 3,
KE 3, DF3, PF 3
NA Severe inflammatory myopathy Polymyositis
18 82 24 M R hand weakness,
then L hand weakness
FF 3R (R); 2 (L) Myopathic Ragged red fibers, COX-negative
fibers
ALS
19 56 60 M Progressive weakness
in hand grip
WF 5−, FF 4 Myopathic NA Possible ALS




EE 4, FF 4, HF 4−,
KE 5−
NA Endomysial mononuclear
infiltration, internal nuclei in many




Abbreviations: ALS amyotrophic lateral sclerosis, B biceps, b/l bilateral, COX cytochrome oxidase, DF dorsiflexors, EE elbow extension, EF elbow flexion, FE finger
extension, FF finger flexion, HA hip abduction, HE hip extension, HF hip flexion, IBM inclusion body myositis, KE knee extension, KF knee flexion, L left, LE lower
extremity, NA not available, PF plantarflexors, pt patient, PT physical therapy, R right, RA rheumatoid arthritis, SA shoulder abduction, s-IBM sporadic inclusion body
myositis, UE upper extremity, WE wrist extension, WF wrist flexion
aStrength is given according to the Medical Research Council grading system. Muscle groups not listed are otherwise normal strength
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may initially show a limited response to corticosteroids.
Other treatments available for inflammatory myopathies
have efficacy in s-IBM in specific cases [3, 16]. Patients
with dysphagia may benefit from intravenous immuno-
globulin (IVIG) therapy, along with balloon dilation or
botulinum toxin injection [16–20]. Although this disease
is rare and incurable, making the correct diagnosis is
crucial to directing the patient to physical therapy for
weakness, gait training, and education to prevent falls.
Occupational therapy may improve a patient’s ability to
engage in activities of daily living. Appropriate patients
with swallowing complaints should be referred to a
speech therapist for proper education regarding diet
consistency and aspiration precautions. Patients may be
assured that s-IBM is not a motor neuron disease or a
rapidly deteriorating myopathic condition that is life-
threatening [6].
Our university neuromuscular clinic sees approximately
six new patients with s-IBM each year. The median age of
the predominantly male population in our present report
was 69 years, and patients’ ages ranged from 43 to 85
years. The median time from symptom onset to final diag-
nosis was 54 months and ranged from 6 months to 20
years, reflective of the slow disease course that helps to
differentiate s-IBM from other disease mimickers. Experi-
enced neurologists and neuromuscular specialists can
diagnose s-IBM based on its topography of weakness of
quadriceps and forearm flexors, but the diagnosis is often
missed, delayed, or incorrect. Common misdiagnoses are
PM, immune-mediated neuromuscular disease, entrap-
ment neuropathies, and motor neuron disease. Erroneous
diagnosis can lead to inappropriate therapy, as illustrated
by some of the cases described here and in a previous re-
port of patients who received years of corticosteroids and
immunosuppressive medication and experienced seriousside effects [6]. IVIG was previously used for treatment of
s-IBM until a controlled clinical trial showed lack of effi-
cacy [2]. Needless surgical treatments for radiculopathy or
entrapment neuropathy have occurred, as illustrated by
patient 5 in our series.
Although s-IBM is a well-recognized neuromuscular
diagnosis that is seen in neurology and neuromuscular
specialty clinics, it is well known that it can masquerade
as other disorders [6]. The cases described here confirm
and highlight the fact that s-IBM is still difficult to diag-
nose and remains frequently misdiagnosed. Our data
show that the time to diagnosis averaged 5.83 years, a
delay similar to that described by Lotz and coworkers in
1989 [21]. The fact that this has remained unchanged
for 25 years is disappointing but not entirely surprising,
given the symptoms and neurological topography, in-
cluding asymmetric weakness, finger flexor weakness,
loss of grip strength, gait difficulty, and dysphagia, that
overlap with those of non-s-IBM conditions. The elec-
trodiagnostic findings in our clinical neurophysiology la-
boratory in this case series also coincide with previous
reports of mixed patterns, which may confuse non-
neuromuscular clinicians.
We find several pitfalls in the diagnosis of s-IBM. First
is an overreliance on electrophysiology. Second, muscle
biopsies sometimes do not have all the cardinal histo-
logical features, including endomysial inflammation,
newer findings of MHC class II upregulation and inva-
sion of non-necrotic muscle fibers by lymphocytes, and
mitochondrial changes [22–24]. Also, clinicians may be
misled by an incomplete biopsy appearance, with patchy
inflammatory changes being more florid early and
patchy degenerative changes more florid later in the dis-
ease course. A third pitfall arises when patients present
early with either atypical symptoms, such as camptocor-
mia or foot drop, or an incomplete clinical picture. Clues
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flexor and quadriceps weakness, as confirmed in our
present study. It has been suggested that s-IBM can be
made by clinical diagnosis alone [25]. To the general prac-
tice clinician, however, we recommend that all cases of
suspected s-IBM be referred to a center specializing in
neuromuscular disease so that an appropriate diagnosis
can be made and inappropriate treatments are avoided.
Limitations of our study include the relatively small
number of patients. Our present study of 20 patients is
only half the number of the series previously reported by
Lotz and colleagues (40 patients) [21]. Also, our study
may have university and/or tertiary geographic referral
bias, along with limitations of our single-center experi-
ence. We do hope that our aforementioned clinical
points are clear, however, regarding potential misdiag-
nosis and the importance of correct diagnosis.
Conclusions
s-IBM is still difficult to diagnose and unfortunately re-
mains frequently misdiagnosed, with a delay in accurate
diagnosis of just over 5½ years, which has not changed
over the last 25 years. Although s-IBM is rare and with-
out effective therapy, accurate diagnosis is of crucial im-
portance to providing adequate patient counseling and
information about the prognosis and course of the dis-
ease. Cases of suspected s-IBM should be referred to a
center specializing in neuromuscular disease so that an
appropriate diagnosis can be made and inappropriate
treatments are avoided.
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patients for publication of this case report and accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Abbreviations
ALS: Amyotrophic lateral sclerosis; b: Biceps; b/l: Bilateral; COX: Cytochrome
oxidase; CK: Creatine kinase; DF: Dorsiflexors; EE: Elbow extension; EF: Elbow
flexion; EMG: Electromyography; FE: Finger extension; FF: Finger flexion;
HA: Hip abduction; HE: Hip extension; HF: Hip flexion; IBM: Inclusion body
myositis; IVIG: Intravenous immunoglobulin; KE: Knee extension; KF: Knee
flexion; LE: Lower extremity; MHC: Major histocompatibility complex;
PF: Plantarflexors; PM: Polymyositis; pt: Patient; PT: Physical therapy; R: Right;
RA: Rheumatoid arthritis; SA: Shoulder abduction; s-IBM: Sporadic inclusion
body myositis; UE: Upper extremity; WE: Wrist extension; WF: Wrist flexion.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AC and SRB examined patients 1 and 2. SRB examined all cases presented in
Table 1. AC wrote the initial manuscript. SRB supervised the coordination of
clinical care, rewrote and edited the manuscript, did an additional literature
search and performed and interpreted all of the electrodiagnostic studies.
RAR reviewed the manuscript and revised and further edited the manuscript
using an additional literature search. SRB and RAR were responsible for the
intellectual content of the report, along with critical appraisals, suggestions
and revisions. All authors participated in and provided significantcontributions to the writing of the manuscript. All authors read and
approved the final manuscript.
Authors’ information
AC is a recent former clinical neurophysiology fellow at the University of
Southern California Keck School of Medicine and Los Angeles County
Medical Center (currently in private practice). SRB is a professor of
neurology at the University of Southern California Keck School of Medicine
and Los Angeles County Medical Center. SRB is director of the University
of Southern California Neuromuscular Program, a fellow of the American
Academy of Neurology and the American Association of Neuromuscular
and Electrodiagnostic Medicine, and board-certified by the American Board
of Psychiatry and Neurology in neurology, clinical neurophysiology, pain
medicine, and neuromuscular medicine. SRB is also board-certified by the
American Board of Electrodiagnostic Medicine in electrodiagnostic medicine.
SRB is a member of the advisory board and the scientific committee of the
Myasthenia Gravis Foundation of California. RAR is a deputy editor of the
Journal of Medical Case Reports; an associate neurology editor of BMC Neurology,
Grand Rounds and WebmedCentral; and a section editor of BMC Research Notes.
RAR practices general neurology at Neurology Consultants Medical Group,
serves as medical director of the PIH Health Hospital-Whittier Stroke Program
and the PIH Health Hospital-Whittier Non-Invasive Vascular Laboratory, is a
clinical assistant professor of neurology at the University of Southern California
Keck School of Medicine and Los Angeles County Medical Center, and is a
fellow of the American Association of Neuromuscular and Electrodiagnostic
Medicine. RAR is board-certified by the American Board of Psychiatry and
Neurology in neurology and vascular neurology, and neurocritical care and
neuroimaging by the United Council of Neurologic Subspecialties. RAR is
also board-certified by the American Board of Electrodiagnostic Medicine
in electrodiagnostic medicine. RAR is a former president of the Los Angeles
Neurological Society and is a fellow of the American Academy of Neurology
and the American Neurological Association.
Acknowledgments
We gratefully acknowledge the patients described in this report. We also
acknowledge and are grateful to Jennifer Kelly Shepphird, PhD, of JKS
Science & Medical Writing, LLC (www.jkswriting.com) for her assistance in
production and revision of Table 1 as well as calculation of some statistics
and general manuscript revision.
Author details
1Neuromuscular Division, Keck School of Medicine, University of Southern
California, 1520 San Pablo Street, Suite 3000, Los Angeles, CA 90033, USA.
2Keck School of Medicine, University of Southern California, Los Angeles
County Medical Center, PIH Health Hospital-Whittier Stroke Program, 12401
Washington Boulevard, Whittier, CA 90602, USA.
Received: 8 January 2015 Accepted: 6 July 2015
References
1. Dalakas MC. Sporadic inclusion body myositis–diagnosis, pathogenesis and
therapeutic strategies. Nat Clin Pract Neurol. 2006;2(8):437–47.
2. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K.
Treatment of inclusion-body myositis with IVIg: a double-bind, placebo-
controlled study. Neurology. 1997;48:712–16.
3. Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci
Rep. 2013;13:321.
4. Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and
pathologic aspects. Neurology. 2006;66(2 Suppl 1):S20–9.
5. Murata KY, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with
sporadic inclusion body myositis (s-IBM). Neurol Sci. 2012;33(4):765–70.
6. Schellenberg KL, Johnston WS, Kalra S, Resch L, Johnson ES. Inclusion body
myositis masquerading as amyotrophic lateral sclerosis. Can J Neurol Sci.
2010;37(5):687–91.
7. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al. The CARE
guidelines: consensus-based clinical case report guideline development.
J Clin Epidemiol. 2014;67(1):46–51.
8. Rison RA, Kidd MR, Koch CA. The CARE (CAse REport) guidelines and the
standardization of case reports. J Med Case Rep. 2013;7:261.
Chilingaryan et al. Journal of Medical Case Reports  (2015) 9:169 Page 6 of 69. Rison RA. A guide to writing case reports for the Journal of Medical Case
Reports and BioMed Central Research Notes. J Med Case Rep. 2013;7:239.
10. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative
muscle disease associated with intra-muscle fiber multi-protein aggregates,
proteasome inhibition, endoplasmic reticulum stress and decreased
lysosomal degradation. Brain Pathol. 2009;19(3):493–506.
11. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 kDa
muscle protein in inclusion body myositis. PLoS One. 2011;6(5):e20266.
12. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al.
Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body
myositis. Ann Neurol. 2013;73(3):408–18.
13. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der
Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase
1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407.
14. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion
body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop,
London, 13 June 2008. Neuromuscul Disord. 2010;20(2):142–7.
15. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and
outcome in PM and sporadic IBM. Neurology. 2008;70(6):418–24.
16. Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol.
2002;14(6):653–7.
17. Breithaupt M, Schmidt J. Update on treatment of inclusion body myositis.
Curr Rheumatol Rep. 2013;15:329.
18. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, et al.
Intravenous immunoglobulin for dysphagia of inclusion body myositis.
Neurology. 2002;58:326.
19. Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic
inclusion body myositis patients with dysphagia. Clin Med Insights Case
Rep. 2013;6:1–7.
20. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction
of the cricopharyngeal muscle with botulinum A toxin: introduction of a
new, noninvasive method. Ann Otol Rhinol Laryngol. 1994;103:31–5.
21. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis:
observations in 40 patients. Brain. 1989;112(Pt 3):727–47.
22. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL.
Prevalence of sporadic inclusion body myositis and factors contributing to
delayed diagnosis. J Clin Neurosci. 2008;15(12):1350–3.
23. Brady S, Squier W, Sewry C, Hanna M, Hilton-Jones D, Holton JL. A
retrospective cohort study identifying the principal pathological features
useful in the diagnosis of inclusion body myositis. BMJ Open.
2014;4:e004552.
24. Rose MR, Working Group ENMCIBM. 188th ENMC International Workshop:
inclusion body myositis, 2–4 December 2011, Naarden, the Netherlands.
Neuromuscul Disord. 2013;23:1044–55.
25. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the
diagnosis of inclusion body myositis independently of pathological features.
J Neurol Neurosurg Psychiatry. 2013;84:1240–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
